Researchers at the La Jolla Institute for Allergy and Immunology have found individuals who had been inoculated with the newer pertussis (whooping cough) vaccine as part of their initial series of shots mount a weaker recall response when receiving booster shots later on.
The U.S. Food and Drug Administration has approved Erleada (apalutamide) to treat men with prostate cancer that has not yet spread but has a quickly rising PSA level while on treatment with hormone therapy, which causes concern for cancer growth and spread.
The Centers for Disease Control andPrevention is warning about a shortage of Shringrix, the newest shingles vaccine recommended for individuals 50 years and older, due to greater-than-expected demand.
The Food and Drug Administration has revised its recommendations for testing blood donations for the Zika virus.
The Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) have updated guidelines for diagnosis and management of Clostridium difficile (C. diff).
A longitudinal study of Canadian boys with severe hemophilia showed that tailored frequency-escalated prophylaxis results in minimal long-term arthropathy and very good health outcomes, while reducing the quantity of costly clotting factor as compared with standard prophylaxis protocols.
Results from a clinical trial have led investigators to conclude adding longterm administration of human albumin to conventional treatment inpatients with decompensated cirrhosis appears to prolong survival.
HIV/AIDS researcher Robert Redfield, MD, has been named the next head of the Centers for Disease Control and Prevention.
The Health and Human Services Notice of Benefit and Payment Parameters for 2019 aims to increase state flexibility, improve affordability, strengthen program integrity, empower consumers, promote stability and reduce unnecessary regulatory burdens imposed by the Patient Protection and Affordable Care Act.
The finalized 2019 Medicare Advantage plan rates will rise an average of 3.4 percent, with other changes being implemented as well.
A pilot study conducted by U.S. investigators observed improvements in cognitive and behavioral function in 14 children with autism spectrum disorder and evidence of immune dysfunction who were administered high-dose intravenous immune globulin (IVIG) treatment over a period of 30 weeks.
New guidance from the Centers for Medicare and Medicaid Services allows work requirements to be used as a basis for eligibility for certain Medicaid beneficiaries.
